Krista F Huybrechts
Biographic Data
| ID | 5542476 |
|---|---|
| NAME | Krista F Huybrechts |
| GIVEN NAMES | Krista F |
| FAMILY NAME | Huybrechts |
| SIGNATURE | HUYBRECHTS K F |
| AFFILIATIONS | Brigham and Women's Hospital |
| ORCID | 0000-0001-5805-8430 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2015 |
| LATEST PUBLICATION YEAR | 2017 |
| H-INDEX | 0 |
The Potential Return on Public Investment in Detecting Adverse Drug Effects
BACKGROUND: Many countries lack fully functional pharmacovigilance programs, and public budgets allocated to pharmacovigilance in industrialized countries remain low due to resource constraints and competing priorities. OBJECTIVE: Using 3 case examples, we sought to estimate the public health and economic benefits resulting from public investment in active pharmacovigilance programs to detect adverse drug effects. RESEARCH DESIGN: We assessed 3 e…
Prescription Drug Insurance Coverage and Patient Health Outcomes
Previous reviews have shown that changes in prescription drug insurance benefits can affect medication use and adherence. We conducted a systematic review of the literature to identify studies addressing the association between prescription drug coverage and health outcomes. Studies were included if they collected empirical data on expansions or restrictions of prescription drug coverage and if they reported clinical outcomes. We found 23 studies…
No prominent works on this page.
Prescription Drug Insurance Coverage and Patient Health Outcomes
Previous reviews have shown that changes in prescription drug insurance benefits can affect medication use and adherence. We conducted a systematic review of the literature to identify studies addressing the association between prescription drug coverage and health outcomes. Studies were included if they collected empirical data on expansions or restrictions of prescription drug coverage and if they reported clinical outcomes. We found 23 studies…
The Potential Return on Public Investment in Detecting Adverse Drug Effects
BACKGROUND: Many countries lack fully functional pharmacovigilance programs, and public budgets allocated to pharmacovigilance in industrialized countries remain low due to resource constraints and competing priorities. OBJECTIVE: Using 3 case examples, we sought to estimate the public health and economic benefits resulting from public investment in active pharmacovigilance programs to detect adverse drug effects. RESEARCH DESIGN: We assessed 3 e…
Actuarial science (1 work) · Advanced Causal Inference Techniques (1 work) · Adverse effect (1 work) · Business (1 work) · Environmental health (1 work) · Medicine (1 work) · Pharmaceutical industry and healthcare (1 work) · Pharmacology (1 work) · Pharmacology (1 work) · Pharmacovigilance (1 work)